

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/517,941
				Filing Date	December 13, 2004
				First Named Inventor	Bakker et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	2578-6723US

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/EGS/		US-5,696,100	12-09-1997	Holme et al.	
		US- 6,265,150	07-24-2001	Terstappen et al.	
		US- 6,312,700	11-06-2001	Weinberg	
		US- 2001/0044522	11-22-2001	Godfrey et al.	
		US- 5,821,332	10-13-1998	Godfrey et al.	
		US- 6,277,862	08-21-2001	Godfrey et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/EGS/		WO 98/15833	04-16-1998	Universiteit Utrecht		
		WO 89/42585	08-26-1999	Sisters of Providence in Oregon		
		WO 95/12673	12-24-2003	Crucell Holland B.V.		
		WO 03/106498	12-24-2003	Crucell Holland B.V.		

Examiner Signature	/Elly Gerald Stoica/	Date Considered	09/19/2007
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/517,941
		Filing Date	December 13, 2004
		First Named Inventor	Bakker et al
		Group Art Unit	To be assigned
		Examiner Name	To be assigned
Sheet 2 of 2	Attorney Docket Number	2578-672311S	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/EGS/		PCT International Search Report, PCT/EP2003/106498, dated January 7, 2004.	
		PCT International Search Report, PCT/EP2003/106498, dated January 7, 2004.	
		VAUGHAN et al., "Human antibodies by design," Nature Biotechnology, June 1998, pp. 535-539, vol. 16.	
		WEINBERG et al., "Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity," Journal of Immunology, 15 February 2000, pp. 2160-2169, vol. 164, no. 4.	
		WEINBERG, A., "OX40: targeted immunotherapy - implications for tempering autoimmunity and enhancing vaccines," Trends in Immunology, February 2002, pp. 102-109, vol. 23, no. 2.	

Examiner Signature	/Elly Gerald Stoica/	Date Considered	09/19/2007
--------------------	----------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.